Search Results 341-350 of 16800 for Selective estrogen receptor modulator
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
The purpose of this study is to to bring molecular risk prediction for breast cancer into the clinical arena through: the establishment of a large tissue ...
Mayo Clinic Comprehensive Cancer Center is one of a select ... If you had radiation, when did you start hormone therapy? ... Hormone therapy for breast cancer ...
Mayo Clinic Oncology — Medical oncologists at Mayo Clinic offer innovative treatments for cancers of the organs, bones, muscles and connective tissues.
The purpose of this study is to evaluate a low-cost Contrast Enhanced Digital Mammogram (CEDM) protocol as a supplemental screening method to standard ...
... estrogen and progesterone receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced ...
It usually occurs in women taking injectable hormone medications to stimulate the development of eggs in the ovaries. Ovarian hyperstimulation syndrome (OHSS) ...
... estrogen-receptor-positive, HER2-negative breast cancers that have not ... Subjects on a stable therapy with a GLP-1 receptor agonist, DPP-4 inhibitor ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.